Mark Baxter

So what we're finding is that

That six months to a year of prolonged therapy after the treatment really makes a difference.

So for me, the take home message I want to pass across to people is that this is not a magic bullet therapy.

You know, for people who are worried well or people who are just, you know, they've got one big issue and other parts of their life are OK.

You know, sometimes it is that magic bullet.

But for people with chronic, enduring mental health issues, this opens a window to a much bigger opportunity.

But also, it can be destabilizing, it can be dysregulating, it can be really tough.

And there's a lot of work to do after the therapy to really put things in place.

But what we're finding in MDMA-assisted therapy in our treatment program and also in the MAPS trials is that people are generally getting better after the year out.

So because the PTSD is relaxed or sort of rescinded a little bit, people are able to start making some changes and they're slowly getting better.

The psilocybin-assisted therapy is a little bit more... We don't have as much good clinical trial data.

There's no phase three trials that have been published yet.

There's only phase two trials, which are much smaller.

So what we can say is not as comprehensive.

Many people are relapsing after six to 12 months.

We're not sure...

why that's happening or who's relapsing and who's not.

We don't have that level of kind of long-term data yet.

Again, in our clinical trial program, we're finding a mixture of people that are getting this beautiful kind of opening and opportunity and relief to then go on and kind of engage in life in a different way.

And we're getting some people who are getting these windows of opening and then going back into depression again.